# NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI

> **NCT07739043** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Cell Therapy LLC** · enrollment: 8 (estimated)

## Conditions studied

- SCI - Spinal Cord Injury
- SCI
- Spinal Cord Injury

## Interventions

- **DRUG:** Human allogeneic, culture expanded, UC-MSC

## Key facts

- **NCT ID:** NCT07739043
- **Lead sponsor:** Cell Therapy LLC
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739043, "NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*